Literature DB >> 25954856

Oncostatin M activates STAT3 to promote endometrial cancer invasion and angiogenesis.

Minjiao Zhu1, Qi Che1, Yun Liao2, Huihui Wang1, Jingyun Wang2, Zheng Chen1, Fangyuan Wang1, Chenjun Dai1, Xiaoping Wan2.   

Abstract

Oncostatin M (OSM), a pleiotropic cytokine, can either promote or inhibit the growth of tumors derived from specific tissues. However, little is known about the activity and expression pattern of OSM in endometrial cancers (ECs). Herein we show that expression of OSM in human ECs was significantly higher than that in hyperplastic or normal tissues. In EC tissues, high OSM levels were positively correlated with tumor stage, histological grade, myometrial invasion, and lymph node metastasis. Additionally, we demonstrated that recombinant human OSM (rhOSM) promoted tumor angiogenesis in EC cell lines by activating STAT3 (signal transducer and activator of transcription 3) and enhanced both cell migration and cell invasion. rhOSM did not, however, influence the proliferation of EC cells in vitro. In contrast, in our in vivo xenograft model, overexpression of rhOSM promoted cell proliferation, tumor growth, and angiogenesis in nude mice. Collectively, these experiments suggest that OSM may be a tumor promoter that encourages EC progression. OSM may thus serve as a potential target of antiangiogenic therapy for endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25954856     DOI: 10.3892/or.2015.3951

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

1.  Prostaglandin E2 triggers cytochrome P450 17α hydroxylase overexpression via signal transducer and activator of transcription 3 phosphorylation and promotes invasion in endometrial cancer.

Authors:  Jieqi Ke; Zhen Shen; Min Li; Cheng Peng; Ping Xu; Meimei Wang; Yi Zhu; Xuefen Zhang; Dabao Wu
Journal:  Oncol Lett       Date:  2018-07-18       Impact factor: 2.967

2.  STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.

Authors:  Benjamin L Bryson; Damian J Junk; Rocky Cipriano; Mark W Jackson
Journal:  Cell Cycle       Date:  2016-11-28       Impact factor: 4.534

3.  Association of STAT3 with Cx26 and Cx43 in human uterine endometrioid adenocarcinoma.

Authors:  Urszula Sulkowska; Andrzej Wincewicz Febp; Stanislaw Sulkowski
Journal:  Oncol Lett       Date:  2016-05-09       Impact factor: 2.967

4.  Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.

Authors:  Jacob M Smigiel; Neetha Parameswaran; Mark W Jackson
Journal:  Mol Cancer Res       Date:  2017-01-04       Impact factor: 6.333

5.  Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer.

Authors:  Jieqi Ke; Yixia Yang; Qi Che; Feizhou Jiang; Huihui Wang; Zheng Chen; Minjiao Zhu; Huan Tong; Huilin Zhang; Xiaofang Yan; Xiaojun Wang; Fangyuan Wang; Yuan Liu; Chenyun Dai; Xiaoping Wan
Journal:  Tumour Biol       Date:  2016-05-26

6.  Human Intervention Study to Assess the Effects of Supplementation with Olive Leaf Extract on Peripheral Blood Mononuclear Cell Gene Expression.

Authors:  Anna Boss; Chi Hsiu-Juei Kao; Pamela M Murray; Gareth Marlow; Matthew P G Barnett; Lynnette R Ferguson
Journal:  Int J Mol Sci       Date:  2016-12-02       Impact factor: 5.923

7.  High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer.

Authors:  John J Wallbillich; Srirama Josyula; Uksha Saini; Roman A Zingarelli; Kalpana Deepa Priya Dorayappan; Maria K Riley; Ross A Wanner; David E Cohn; Karuppaiyah Selvendiran
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

8.  Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.

Authors:  Giulia Bottai; Lixia Diao; Keith A Baggerly; Laura Paladini; Balázs Győrffy; Carlotta Raschioni; Lajos Pusztai; George A Calin; Libero Santarpia
Journal:  Int J Mol Sci       Date:  2017-01-19       Impact factor: 5.923

Review 9.  Cancer Stem Cell Plasticity Drives Therapeutic Resistance.

Authors:  Mary R Doherty; Jacob M Smigiel; Damian J Junk; Mark W Jackson
Journal:  Cancers (Basel)       Date:  2016-01-05       Impact factor: 6.639

10.  Oncostatin M is a novel biomarker for coronary artery disease - A possibility as a screening tool of silent myocardial ischemia for diabetes mellitus.

Authors:  Shohei Ikeda; Koichi Sato; Morihiko Takeda; Keita Miki; Kentaro Aizawa; Tsuyoshi Takada; Koji Fukuda; Nobuyuki Shiba
Journal:  Int J Cardiol Heart Vasc       Date:  2021-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.